Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab vs Observation in Mucosal Melanoma
NCT03220009Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in mucosal melanoma (MM) comparing Observation with Adjuvant Nivolumab (2 arms). Primary endpoint: Recurrence Free Survival up to 5 years. Planned start Nov 2017; status: withdrawn.
02
Drugs
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03220009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220009.